biohaven: "rimegepant pivotal phase 3 trial results -- conference call.".

it's not clear how well they'll stack up against current migraine therapies, because head-to-head studies haven't been done..

.

but shocking figures uncovered by labour yesterday show some patients are suffering agonising waits of as many as 541 days to begin treatment....

0 comments

..

https://drbryanpwalsh.com/Bosak-grandpa-of-Barrientes-from-Trivandrum?Belowdaug=190

staff blog: medicine matters

.

subscribe to breaking news emails

.

eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention...

find this comment offensive?

.

home

.. march 2016  (31).